… Enrolled patients entered a 2-week run-in period and were subsequently randomised to
receive 28 days of study treatment, with a 7-day follow-up period to monitor AEs after study-drug …

… of the β 2 agonists. Therefore, we performed a systematic review and meta-analysis of the
published RCTs, on the effects of β 2 agonists on hospital mortality, 28-day mortality, and …

… for 28 days. The primary end point was change from baseline in trough FEV 1 at the end of
the 28-day … Secondary end points included 0- to 24-h weighted mean FEV 1 on days 1 and 28 …

… Indacaterol is a novel once-daily β 2 -agonist that has demonstrated 24-hour bronchodilator
… The primary objective of this study was to evaluate the safety and tolerability of 28 days of …

… Desensitization of β 2 -adrenoceptors that occurs during the first few days of regular use
of β 2 -agonist … can provoke direct simulation of the heart (1, 28). Moreover, stimulation of …

… , with each test-day separated by a washout period of at least 14 days. Following … day,
patients were required to withdraw inhaled short-acting bronchodilators (8-h) and long-acting β 2 …

… The primary outcome was death within 28 days of randomisation. Analysis was by
intention-to-treat. This trial is registered, ISRCTN38366450 and EudraCT number 2006-002647-86. …

… A 28 day study in patients ≥12 years with persistent asthma on maintenance ICS showed
that once-daily vilanterol was well tolerated and resulted in a prolonged duration of action of …

… 500 μ g twice a day) and 28 normal subjects without asthma … μ g twice a day, fluticasone
propionate 100 μ g twice a day, or … 34 of the subjects with asthma and 28 of the normal subjects. …

… However, after 28 days of continuous treatment, the bronchoprotective effect was markedly
reduced and was only significantly greater than placebo at 1 h post-administration but not 9 h …